5:58 PM
 | 
Oct 24, 2008
 |  BC Extra  |  Clinical News

Researchers report role of BRAF mutation for mCRC drugs

Researchers at the University of Turin School of Medicine found that colorectal cancer tumors with a mutation in the BRAF gene do not respond to Vectibix panitumumab or Erbitux cetuximab. The group did find that Nexavar sorafenib restores the tumors' sensitivity to the EGFR-targeting mAbs.

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >